| Title |
Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects
|
|---|---|
| Published in |
Journal of Neural Transmission, March 2018
|
| DOI | 10.1007/s00702-018-1876-2 |
| Pubmed ID | |
| Authors |
Peter Riederer, Thomas Müller |
| Abstract |
This invited narrative review emphasizes the role of MAO-B inhibition in the drug portfolio for dopamine substitution in patients with Parkinson's disease. Neuronal and glial MAO-B inhibition contributes to more stable levels of dopamine and other biogenic amines in the synaptic cleft. Accordingly, symptomatic effects of MAO-B inhibition for a limited amelioration of impaired motor behaviour and wearing-off phenomena in patients with Parkinson's disease are well proven, even when MAO-B inhibitors are only applied together with dopamine agonists. Delay of disease progression by MAO-B inhibition is under debate despite positive experimental findings. This discussion does not consider, that levodopa, respectively, dopamine agonists, are substrates, respectively, inhibitors of the ABCB1 (P-gp, MDR1, and CD243) transporter system. It supports toxin efflux over the blood-brain barrier. ABCB1 transporters have a limited capacity. MAO-B inhibitors do not weaken it. Treatment with MAO-B inhibitors is advantageous as it enables sparing of dopamine agonist and levodopa dosing. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 77 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 17% |
| Student > Master | 11 | 14% |
| Other | 7 | 9% |
| Researcher | 6 | 8% |
| Student > Postgraduate | 5 | 6% |
| Other | 9 | 12% |
| Unknown | 26 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 13% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Medicine and Dentistry | 7 | 9% |
| Neuroscience | 6 | 8% |
| Agricultural and Biological Sciences | 5 | 6% |
| Other | 12 | 16% |
| Unknown | 30 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2018.
All research outputs
#18,591,506
of 23,028,364 outputs
Outputs from Journal of Neural Transmission
#1,445
of 1,783 outputs
Outputs of similar age
#258,245
of 332,500 outputs
Outputs of similar age from Journal of Neural Transmission
#11
of 21 outputs
Altmetric has tracked 23,028,364 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,783 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,500 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.